The U.S. Food and Drug Administration (FDA) has officially removed Ozempic and Wegovy, two widely used medications for weight loss and diabetes, from its drug shortage list. This announcement comes as a relief after a yearslong shortage of these popular drugs, as reported by The Associated Press. Following the FDA’s statement, shares of Hims & Hers, a telehealth company offering generic alternatives to semaglutide, plummeted by 26%, according to CNBC. Bloomberg highlighted that the end of Novo Nordisk’s Ozempic shortage could significantly affect competitors producing copycat versions of the drug. This development marks a pivotal moment in the pharmaceutical market as supply stabilizes. — news from The Hill